The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Open accessAbstract
There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease. Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function. We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to the precision afforded by complementary binding of an ASO to its target transcript of interest, ASOs have emerged as an invaluable tool in specifically altering levels and/or processing of a variety of proteins involved in neurodegenerative diseases, most of which have been the disease-causing protein itself (38, 51–54).”
From Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration (2023) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q.-W., Eliason, S., Harper, S., Martins, I. H., Orr, H., Paulson, H., Yang, L., Kotin, R., & Davidson, B. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 689
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationTherapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Self-citationSwayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 483
Self-citationThe genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 331
Huynh, D. P., Figueroa, K. P., Hoang, N., & Pulst, S.-M. (2000) · Nature Genetics · doi:10.1038/79162 · Cited by 330
Self-citationDeranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 2
Liu, J., Tang, T.-S., Tu, H., Nelson, O. L., Herndon, E., Huynh, D. P., Pulst, S. M., & Борисович, Б. И. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0660-09.2009 · Cited by 299
Self-citationCarroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N. H., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
Self-citationHansen, S. T., Meera, P., Otis, T. S., & Pulst, S. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds427 · Cited by 173
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 318
Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion
Niewiadomska-Cimicka, A., Hache, A., & Trottier, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00571 · Cited by 42
Staufen1 in Human Neurodegeneration
Paul, S., Dansithong, W., Figueroa, K. P., Gandelman, M., Scoles, D. R., & Pulst, S. M. (2021) · Annals of Neurology · doi:10.1002/ana.26069 · Cited by 40
Self-citationBaicalin Promotes CNS Remyelination via PPARγ Signal Pathway
Ai, R.-S., Xing, K., Deng, X., Han, J.-J., Hao, D.-X., Qi, W.-H., Han, B., Yang, Y.-N., Li, X., & Zhang, Y. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001142 · Cited by 41
Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA)
Prestori, F., Moccia, F. D., & D'Angelo, E. U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010216 · Cited by 40
MicroRNAs As Master Regulators of Atherosclerosis: From Pathogenesis to Novel Therapeutic Options
Hosen, M. R., Goody, P. R., Zietzer, A., Nickenig, G., & Jansen, F. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8107 · Cited by 40
Shi, X., Xu, Y., Wang, B., Li, Z., Yu, S., Dong, H., Zhao, W., Jiang, D., Chen, H., & Xu, J. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202302930 · Cited by 39
Alternative splicing in aging and age-related diseases
Li, H., Wang, Z., Ma, T., Wei, G., & Ni, T. (2017) · Translational Medicine of Aging · doi:10.1016/j.tma.2017.09.005 · Cited by 40
Altered synaptic and firing properties of cerebellar Purkinje cells in a mouse model of ARSACS
Ady, V., Toscano‐Márquez, B., Nath, M., Chang, P. K. ‐., Hui, J., Cook, A. A., Charron, F. M., Larivière, R., Brais, B., McKinney, R. A., et al. (2018) · The Journal of Physiology · doi:10.1113/jp275902 · Cited by 39
Current Opinions and Consensus for Studying Tremor in Animal Models
Kuo, S., Louis, E. D., Faust, P. L., Handforth, A., Chang, S.-Y., Avlar, B., Lang, E. J., Pan, M., Miterko, L. N., Brown, A. M., et al. (2019) · The Cerebellum · doi:10.1007/s12311-019-01037-1 · Cited by 38
Self-citationAntisense therapies for movement disorders
Scoles, D. R., & Pulst, S. M. (2019) · Movement Disorders · doi:10.1002/mds.27782 · Cited by 39
Self-citationFetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
Wang, L., Kempton, J. B., Jiang, H., Jodelka, F. M., Brigande, A. M., Dumont, R. A., Rigo, F., Lentz, J. J., Hastings, M. L., & Brigande, J. V. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa194 · Cited by 44
Self-citationArsović, A., Halbach, M. V., Canet-Pons, J., Esen-Sehir, D., Döring, C., Freudenberg, F., Czechowska, N., Seidel, K., Baader, S. L., Gispert, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186673 · Cited by 35
Poly(A)-Binding Protein Is an Ataxin-2 Chaperone That Emulsifies Biomolecular Condensates
Boeynaems, S., Dorone, Y., Zhuang, Y., Shabardina, V., Huang, G., Marian, A., Kım, G., Sanyal, A., Şen, N.-E., Griffith, D., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2023.05.025 · Cited by 41
Şen, N.-E., Arsović, A., Meierhofer, D., Brodesser, S., Oberschmidt, C., Canet-Pons, J., Güleç, Z. E. K., Halbach, M. V., Gispert, S., Sandhoff, K., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235854 · Cited by 35
The neurological update: therapies for cerebellar ataxias in 2020
Gandini, J., Manto, M. U., Brémovà-Ertl, T., Feil, K., & Strupp, M. L. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09717-3 · Cited by 36
Cendelín, J., Cvetanović, M., Gandelman, M., Hirai, H., Orr, H. T., Pulst, S. M., Strupp, M., Tichánek, F., Tůma, J., & Manto, M. U. (2021) · The Cerebellum · doi:10.1007/s12311-021-01311-1 · Cited by 37
Self-citationAutosomal-dominant cerebellar ataxias
Mundwiler, A., & Shakkottai, V. G. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00012-9 · Cited by 34
Velez, M. V. L., Verhaegh, G. W. C. T., Smit, F. P., Sedelaar, J. P. M., & Schalken, J. A. (2019) · Oncogene · doi:10.1038/s41388-019-0696-7 · Cited by 35
Collaborative Efforts for Spinocerebellar Ataxia Research in the United States: CRC-SCA and READISCA
Lin, C.-C., Ashizawa, T., & Kuo, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00902 · Cited by 34
Nigri, A., Sarro, L., Mongelli, A., Pinardi, C., Porcu, L., Castaldo, A., Ferraro, S., Grisoli, M., Bruzzone, M. G., Gellera, C., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.616419 · Cited by 37
Sacs R272C missense homozygous mice develop an ataxia phenotype
Larivière, R., Sgarioto, N., Toscano‐Márquez, B., Gaudet, R., Choquet, K., McKinney, R. A., Watt, A. J., & Brais, B. (2019) · Molecular Brain · doi:10.1186/s13041-019-0438-3 · Cited by 33
de Sá, R. V., Sudrià-Lopez, E., Luna, M. C., Harschnitz, O., van den Heuvel, D. M. A., Kling, S., Vonk, D., Westeneng, H., Karst, H., Bloemenkamp, L. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51676-0 · Cited by 37
Therapeutic antisense oligonucleotides for movement disorders
Doxakis, E. (2020) · Medicinal Research Reviews · doi:10.1002/med.21706 · Cited by 34
Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation
Singh, A., Huelsmeier, J., Kandi, A. R., Pothapragada, S. S., Hillebrand, J., Petrauskas, A., Agrawal, K., Krishnan, R., Thiagarajan, D., Jayaprakashappa, D., et al. (2021) · eLife · doi:10.7554/elife.60326 · Cited by 32
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives
Vázquez‐Mojena, Y., León‐Arcia, K., González-Zaldívar, Y., Rodríguez‐Labrada, R., & Velázquez‐Pérez, L. (2021) · Movement Disorders · doi:10.1002/mds.28819 · Cited by 34
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD
Tang, X., Toro, A., Sahana, T. G., Gao, J., Chalk, J. L., Oskarsson, B., & Zhang, K. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00383-7 · Cited by 34
Nanocarriers for Delivery of Oligonucleotides to the CNS
Male, D. K., & Gromnicova, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020760 · Cited by 32
Han, B., Li, X., Deng, S.-Y., Ye, Z.-Q., Ai, R.-S., Deng, X., Ma, W., Xiao, S., Wang, J.-Z., Wang, L.-M., et al. (2022) · eLife · doi:10.7554/elife.72247 · Cited by 31
Velázquez‐Pérez, L., Rodríguez‐Labrada, R., Torres‐Vega, R., Ortega-Sánchez, R., Medrano‐Montero, J., González-Piña, R., Vázquez‐Mojena, Y., Auburger, G. W. J., & Ziemann, U. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.01.066 · Cited by 32
ALS-associated genes in SCA2 mouse spinal cord transcriptomes
Scoles, D. R., Dansithong, W., Pflieger, L. T., Paul, S., Gandelman, M., Figueroa, K. P., Rigo, F., Bennett, C. F., & Pulst, S. M. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa072 · Cited by 33
Self-citationNanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier
Amulya, E., Sikder, A., Vambhurkar, G. B., Shah, S., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.031 · Cited by 30
Mid-Gestation lethality of Atxn2l-Ablated Mice
Key, J., Harter, P. N., Şen, N.-E., Gradhand, E., Auburger, G. W. J., & Gispert, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145124 · Cited by 30
Molecular Mechanisms in Pentanucleotide Repeat Diseases
Loureiro, J. R., Castro, A. F., Figueiredo, A. S., & Silveira, I. (2022) · Cells · doi:10.3390/cells11020205 · Cited by 28
Wan, J.-L., Wang, B., Wu, M.-L., Li, J., Gong, R.-M., Song, L.-N., Zhang, H., Zhu, G., Chen, S.-P., Cai, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215750 · Cited by 29
Staufen Impairs Autophagy in Neurodegeneration
Paul, S., Dansithong, W., Gandelman, M., Figueroa, K. P., Zu, T., Ranum, L. P. W., Scoles, D. R., & Pulst, S. M. (2022) · Annals of Neurology · doi:10.1002/ana.26515 · Cited by 32
Self-citationGenome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2
Kım, G., Nakayama, L., Blum, J. A., Akiyama, T., Boeynaems, S., Chakraborty, M., Couthouis, J., Tassoni-Tsuchida, E., Rodriguez, C. M., Bassik, M. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111508 · Cited by 30
Recent insights into the cellular and molecular determinants of aging
Ruan, L., Zhang, X., & Li, R. (2018) · Journal of Cell Science · doi:10.1242/jcs.210831 · Cited by 28
An Overview of the Current State and the Future of Ataxia Treatments
Kwei, K., & Kuo, S. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.01.008 · Cited by 27
Krahe, J., Binkofski, F., Schulz, J. B., Reetz, K., & Romanzetti, S. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.019 · Cited by 27
Chaudhry, A., Athanasiou‐Fragkouli, A., & Houlden, H. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10218-6 · Cited by 27
Rodríguez‐Labrada, R., Velázquez‐Pérez, L., Ortega-Sánchez, R., Peña-Acosta, A., Vázquez‐Mojena, Y., Canales‐Ochoa, N., Medrano‐Montero, J., Torres‐Vega, R., & González-Zaldívar, Y. (2019) · Cerebellum & Ataxias · doi:10.1186/s40673-019-0097-2 · Cited by 28
Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias
Afonso‐Reis, R., Afonso, I. T., & Nóbrega, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084249 · Cited by 26
Recent advances in molecular therapies for neurological disease: triplet repeat disorders
Gonzalez‐Alegre, P. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz138 · Cited by 27
Current AAV-mediated gene therapy in sensorineural hearing loss
Qi, J., Fu, X., Zhang, L., Tan, F., Li, N., Sun, Q., Hu, X., He, Z., Xia, M., & Chai, R. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.08.015 · Cited by 24
Noncoding repeat expansions for ALS in Japan are associated with the ATXN8OS gene
Hirano, M., Samukawa, M., Isono, C., Saigoh, K., Nakamura, Y., & Kusunoki, S. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000252 · Cited by 23
McIntosh, C. S., Li, D., Wilton, S. D., & Aung-Htut, M. T. (2021) · Biomedicines · doi:10.3390/biomedicines9111499 · Cited by 26
Yang, L., Shao, Y.-R., Li, X., Ma, Y., Dong, Y., & Wu, Z. (2021) · Neurology · doi:10.1212/wnl.0000000000012945 · Cited by 24
Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
Aung-Htut, M. T., McIntosh, C. S., Ham, K. A., Pitout, I. L., Flynn, L. L., Greer, K., Fletcher, S., & Wilton, S. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205030 · Cited by 23
Recent Advances in the Treatment of Cerebellar Disorders
Mitoma, H., Manto, M. U., & Gandini, J. (2019) · Brain Sciences · doi:10.3390/brainsci10010011 · Cited by 26
Changes in protein function underlie the disease spectrum in patients with CHIP mutations
Madrigal, S. C., McNeil, Z., Sanchez‐Hodge, R., Shi, C., Patterson, C., Scaglione, K. M., & Schisler, J. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011173 · Cited by 23
Eklund, N. M., Ouillon, J. S., Pandey, V., Stephen, C. D., Schmahmann, J. D., Edgerton, J. R., Gajos, K. Z., & Gupta, A. S. (2023) · Brain Communications · doi:10.1093/braincomms/fcad064 · Cited by 21
Rodríguez‐Labrada, R., Galicia-Polo, L., Canales‐Ochoa, N., Voss, U., Tuin, I., Peña-Acosta, A., Estupiñán‐Rodríguez, A., Medrano‐Montero, J., Vázquez‐Mojena, Y., González-Zaldívar, Y., et al. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.04.005 · Cited by 24
Liu, Y., Wang, Z., Cao, C., Xu, Z., Lü, J., Shen, H., Li, X., Li, H., Wu, J., & Chen, G. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8808677 · Cited by 21
RetractedTargeted intraspinal injections to assess therapies in rodent models of neurological disorders
Chen, K. S., McGinley, L. M., Kashlan, O. N., Hayes, J. M., Bruno, E. S., Chang, J. S., Mendelson, F. E., Tabbey, M. A., Johe, K. K., Sakowski, S. A., et al. (2019) · Nature Protocols · doi:10.1038/s41596-018-0095-5 · Cited by 22
The molecular pathogenesis of repeat expansion diseases
Fujino, Y., & Nagai, Y. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200143 · Cited by 20
Scoles, D. R., Gandelman, M., Paul, S., Dexheimer, T. S., Dansithong, W., Figueroa, K. P., Pflieger, L. T., Redlin, S., Kales, S. C., Sun, H., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102228 · Cited by 19
Self-citationCoarelli, G., Dubec‐Fleury, C., Petit, E., Sayah, S., Fischer, C., Nassisi, M., Gatignol, P., Dorgham, K., Daghsen, L., Daye, P. M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209749 · Cited by 20
Derzhalova, A. S., Markov, O. V., Фокина, А. А., Shiohama, Y., Zatsepin, T. S., Fujii, M., Аркадьевна, З. М., & Stetsenko, D. A. (2021) · Applied Sciences · doi:10.3390/app11031174 · Cited by 19
Azami, H., Chang, Z., Arnold, S. E., Sapiro, G., & Gupta, A. S. (2022) · IEEE Access · doi:10.1109/access.2022.3156964 · Cited by 19
Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?
Pilotto, F., Bondio, A. D., & Puccio, H. M. (2024) · Cells · doi:10.3390/cells13040319 · Cited by 25
Liao, X., Zhang, S., Li, X., Qian, W., Li, M., Chen, S., Wu, X., Yu, X., Li, Z., Tang, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado1573 · Cited by 18
Castro, A. F., Loureiro, J. R., Bessa, J., & Silveira, I. (2020) · Genes · doi:10.3390/genes11121418 · Cited by 18
Tejwani, L., Jung, Y., Kokubu, H., Sowmithra, S., Ni, L., Lee, C., Sanders, B., Lee, P. J., Xiang, Y., Luttik, K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci138207 · Cited by 17
“been the disease-causing protein itself (33, 42-45).”
Self-citationMaguire, J. A., Gagne, A. L., Gonzalez‐Alegre, P., Davidson, B. L., Shakkottai, V. G., Gadue, P. J., & French, D. L. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.101361 · Cited by 17
Srinivasan, S. R., & Shakkottai, V. G. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00763-y · Cited by 19
DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases
Zhang, N., Bewick, B., Schultz, J., Tiwari, A., Krencik, R., Zhang, A., Adachi, K., Xia, G., Yun, K., Sarkar, P. S., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01075-w · Cited by 16
Egorova, P. A., & Борисович, Б. И. (2022) · The Cerebellum · doi:10.1007/s12311-021-01349-1 · Cited by 16
Huang, H., & Shakkottai, V. G. (2023) · Life · doi:10.3390/life13061350 · Cited by 15
Novel regulators of PrP C expression as potential therapeutic targets in prion diseases
Baldeschi, A. C., Vanni, S., Zattoni, M., & Legname, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1782384 · Cited by 16
Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias
Hommersom, M. P., Buijsen, R. A. M., van Roon‐Mom, W., van de Warrenburg, B. P. C., & van Bokhoven, H. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10184-0 · Cited by 15
Zebrafish Models of Autosomal Dominant Ataxias
Quelle‐Regaldie, A., Sobrido‐Cameán, D., Barreiro‐Iglesias, A., Sobrido, M. J., & Sanchez, L. E. (2021) · Cells · doi:10.3390/cells10020421 · Cited by 15
Mechanistic and Therapeutic Insights into Ataxic Disorders with Pentanucleotide Expansions
Zhang, N., & Ashizawa, T. (2022) · Cells · doi:10.3390/cells11091567 · Cited by 14
Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2
Rodriguez, C. M., Bechek, S. C., Jones, G. L., Nakayama, L., Akiyama, T., Kım, G., Solow-Cordero, D. E., Strittmatter, S. M., & Gitler, A. D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111505 · Cited by 15
Petrauskas, A., Fortunati, D. L., Singh, A., Kandi, A. R., Pothapragada, S. S., Agrawal, K., Huelsmeier, J., Hillebrand, J., Brown, G., Chaturvedi, D., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011251 · Cited by 16
Ashizawa, A. T., Holt, J., Faust, K., Liu, W., Tiwari, A., Zhang, N., & Ashizawa, T. (2018) · The Cerebellum · doi:10.1007/s12311-018-0961-2 · Cited by 15
Ostrowski, L., Hall, A. C., Szafranski, K., Oshidari, R., Abraham, K. J., Chan, J. N. Y., Krustev, C., Zhang, K., Wang, A. C., Liu, Y., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0187-3 · Cited by 14
The complex structure of ATXN2 genetic variation
Pulst, S. M. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000299 · Cited by 14
Self-citationAlmaguer‐Mederos, L. E., Pérez‐Ávila, I., Aguilera‐Rodríguez, R., Velázquez‐Garcés, M., Almaguer‐Gotay, D., Pupo, R. H., Estupiñán‐Rodríguez, A., & Auburger, G. W. J. (2021) · Movement Disorders · doi:10.1002/mds.28498 · Cited by 11
Borbolla‐Jiménez, F. V., Prado-Audelo, M. L. D., Cisneros, B., Caballero-Florán, I. H., Leyva‐Gómez, G., & Magaña, J. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071018 · Cited by 13
Control of CNS Functions by RNA-Binding Proteins in Neurological Diseases
Zhou, Y., Dong, F., & Mao, Y. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0140-7 · Cited by 14
GNG13 Is a Potential Marker of the State of Health of Alzheimer’s Disease Patients’ Cerebellum
Sanfilippo, C., Musumeci, G., Kazakova, M., Mazzone, V., Castrogiovanni, P., Imbesi, R., & Rosa, M. D. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01726-1 · Cited by 14
Myelinating Glia: Potential Therapeutic Targets in Polyglutamine Spinocerebellar Ataxias
Putka, A. F., Mato, J. P., & McLoughlin, H. S. (2023) · Cells · doi:10.3390/cells12040601 · Cited by 12
Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models
Cvetanović, M., & Gray, M. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01357-5 · Cited by 12
Promising therapeutic aspects in human genetic imprinting disorders
Chao, Y., Qin, Y., Zou, X., Wang, X., Hu, C., Xia, F., & Zou, C. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01369-6 · Cited by 14
Liu, C. J., Rainwater, O., Clark, H. B., Orr, H. T., & Akkin, T. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.003 · Cited by 11
Park, S., Park, S.-K., Watanabe, N., Hashimoto, T., Iwatsubo, T., Shelkovnikova, T. A., & Liebman, S. W. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008308 · Cited by 11
Polyglutamine spinocerebellar ataxias: emerging therapeutic targets
Neves‐Carvalho, A., Duarte‐Silva, S., Teixeira‐Castro, A., & Maciel, P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1827394 · Cited by 11
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders
Bizot, F., Vulin, A., & Goyenvalle, A. (2020) · Drugs · doi:10.1007/s40265-020-01363-3 · Cited by 12
Pre-ataxic loss of intrinsic plasticity and motor learning in a mouse model of SCA1
Osório, C., White, J. J., Lu, H., Beekhof, G. C., Fiocchi, F. R., Andriessen, C. A., Dijkhuizen, S., Post, L. C., & Schonewille, M. (2022) · Brain · doi:10.1093/brain/awac422 · Cited by 13
At-home wearables and machine learning capture motor impairment and progression in adult ataxias
Manohar, R., Yang, F. X., Stephen, C. D., Schmahmann, J. D., Eklund, N. M., & Gupta, A. S. (2025) · Brain · doi:10.1093/brain/awaf154 · Cited by 12
Bonsor, M., Ammar, O., Schnoegl, S., Wanker, E. E., & Ramos, E. S. (2024) · PROTEOMICS · doi:10.1002/pmic.202300114 · Cited by 10
Emerging therapies in hereditary ataxias
Eisel, M. L. S., Burns, M., Ashizawa, T., Byrne, B. J., Corti, M., & Subramony, S. H. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.008 · Cited by 10
Dual stimuli-responsive saccharide core based nanocarrier for efficient Birc5-shRNA delivery
Chen, H., Ma, Y., Lan, H., Zhao, Y., Zhi, D., Cui, S., Du, J., Zhang, Z., Zhen, Y., & Zhang, S. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01683f · Cited by 10
Zhang, Y., Quraishi, I. H., McClure, H., Williams, L. A., Cheng, Y., Kale, S., Dempsey, G. T., Agrawal, S., Gerber, D. J., McManus, O. B., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101356r · Cited by 10
van der Bent, M. L., Filho, O. P. D. S., van Luijk, J. A. K. R., Brock, R. E., & Wansink, D. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22316-7 · Cited by 11
Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseasePreprint
Cole, T. A., Zhao, H. T., Collier, T. J., Sandoval, I. M., Sortwell, C. E., Steece‐Collier, K., Daley, B. F., Booms, A., Lipton, J. W., Welch, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/830554 · Cited by 10
Self-citationPoly(A)-Binding Protein Is an Ataxin-2 Chaperone That Emulsifies Biomolecular CondensatesPreprint
Boeynaems, S., Dorone, Y., Marian, A., Shabardina, V., Huang, G., Kım, G., Sanyal, A., Şen, N.-E., Docampo, R., Ruiz‐Trillo, I., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3917156 · Cited by 10
Bux, J., Şen, N.-E., Klink, I.-M., Hauser, S., Synofzik, M., Schöls, L. J., Auburger, G. W. J., Rieß, O., & Hübener‐Schmid, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03294-y · Cited by 9
Key, J., Almaguer-Mederos, L. E., Kandi, A. R., Şen, N.-E., Gispert, S., Koepf, G., Meierhofer, D., & Auburger, G. W. J. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106903 · Cited by 10
Slc9a6 mutation causes Purkinje cell loss and ataxia in the shaker rat
Figueroa, K. P., Anderson, C. J., Paul, S., Dansithong, W., Gandelman, M., Scoles, D. R., & Pulst, S. M. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad004 · Cited by 9
Self-citation
Metadata
- Authors
- Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., & Pulst, S. M.
- Affiliations
- University of Utah (US)
- University of California, Los Angeles (US)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Scoles, Daniel R.
- Pulst, Stefan M.
- ORCID
- Venue
- Nature
- Published
- 2017-04-12
- Volume
- 544
- Issue
- 7650
- Pages
- 362-366
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6625650
- OpenAlex
- W2606911774
- Cited by
- 319
- References
- 31
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 26 · 2023: 28 · 2022: 39 · 2021: 37 · 2020: 37 · 2019: 43 · 2018: 45 · 2017: 21
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Target ALS
- National Institute of Neurological Disorders and Stroke (U01NS103883, R01NS033123, R01NS090930, R21NS081182, RC4NS073009, R56NS033123, R01NS097903, R37NS033123, R21NS103009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- spinocerebellar ataxia type 2, antisense oligonucleotides, ATXN2, polyglutamine expansion, Purkinje cells, TDP-43 aggregation, amyotrophic lateral sclerosis, RNA-targeted therapeutics, neurodegeneration, mouse model, motor function, lifespan
- MeSH terms
- Ataxin-2, Action Potentials, Animals, Disease Models, Animal, Female, Gene Expression Regulation, Humans, Male, Mice, Transgenic, Movement, Phenotype, Purkinje Cells, RNA, Messenger, Oligonucleotides, Antisense, Spinocerebellar Ataxias, Rotarod Performance Test, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
